The presence of oxidative stress in immature brain has been demonstrated during the acute phase of status epilepticus (SE). The knowledge regarding the long periods of survival after SE is not unequivocal, lacking direct evidence. To examine the presence and time profile of oxidative stress, its functional effect on mitochondria and the influence of an antioxidant treatment in immature rats during epileptogenesis, status epilepticus (SE) was induced in immature 12-day-old rats by Li-pilocarpine and at selected periods of the epileptogenesis; rat pups were subjected to examinations. Hydroethidine method was employed for detection of superoxide anion (O2.-), 3-nitrotyrosine (3-NT), and 4-hydroxynonenal (4-HNE) for oxidative damage of mitochondrial proteins and complex I activity for mitochondrial function. Natural polyphenolic antioxidant resveratrol was given in two schemes: "acute treatment," i.p. administration 30 min before, 30 and 60 min after induction of SE and "full treatment" when applications continued once daily for seven consecutive days (25 mg/kg each dose). The obtained results clearly document that the period of epileptogenesis studied (up to 4 weeks) in immature brain is associated with the significant enhanced production of O2.-, the increased levels of 3-NT and 4-HNE and the persisting deficiency of complex I activity. Application of resveratrol either completely prevented or significantly reduced markers both of oxidative stress and mitochondrial dysfunction. The findings suggest that targeting oxidative stress in combination with current antiepileptic therapies may provide a benefit in the treatment of epilepsy.

Institute of Physiology of the Czech Academy of Sciences Vídeňská 1083 142 20 Prague 4 Czech Republic

Zobrazit více v PubMed

Pharmacol Ther. 2011 Sep;131(3):269-86 PubMed

Neurochem Int. 2010 Feb;56(3):394-403 PubMed

Free Radic Biol Med. 2000 Apr 15;28(8):1214-21 PubMed

Free Radic Biol Med. 2006 Dec 1;41(11):1694-703 PubMed

Epilepsy Res. 2010 Jan;88(1):23-45 PubMed

Biochim Biophys Acta. 2014 Feb;1840(2):739-44 PubMed

Epilepsia. 2008 Oct;49(10):1733-48 PubMed

J Neurochem. 2010 Dec;115(5):1172-82 PubMed

Neurochem Int. 2011 Aug;59(2):122-37 PubMed

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7607-12 PubMed

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19126-31 PubMed

Brain Res. 2013 Jan 25;1492:122-9 PubMed

Brain. 2017 Jul 1;140(7):1885-1899 PubMed

Pediatr Res. 2004 Oct;56(4):656-62 PubMed

Eur J Neurosci. 2004 Jun;19(12):3255-65 PubMed

Neurochem Res. 2009 Aug;34(8):1393-400 PubMed

Neuroscience. 2000;97(3):431-5 PubMed

Neuroscience. 2013 Jun 25;241:80-8 PubMed

Biochim Biophys Acta. 1998 May 6;1364(2):271-86 PubMed

Biochem Pharmacol. 2010 Oct 15;80(8):1260-5 PubMed

J Neurochem. 2003 Jan;84(1):112-8 PubMed

J Biol Chem. 1998 Jun 5;273(23):14085-9 PubMed

Int J Dev Neurosci. 2013 Apr;31(2):123-30 PubMed

Brain Res. 2014 Jan 28;1544:54-61 PubMed

Biochem J. 2006 Mar 15;394(Pt 3):627-34 PubMed

Ann Neurol. 2013 Oct;74(4):560-8 PubMed

J Biol Chem. 2006 Apr 14;281(15):10056-65 PubMed

J Biol Chem. 2004 Feb 6;279(6):4127-35 PubMed

Ann Neurol. 2000 Nov;48(5):766-73 PubMed

Physiol Res. 2013;62(Suppl 1):S39-48 PubMed

Eur J Neurosci. 2002 Apr;15(7):1105-14 PubMed

Exp Neurol. 2012 Jan;233(1):421-9 PubMed

Neuroscience. 2013 Apr 3;235:232-49 PubMed

Neurobiol Dis. 2012 Aug;47(2):145-54 PubMed

J Biol Chem. 2003 Sep 26;278(39):37223-30 PubMed

Curr Med Chem. 2010;17(23):2442-55 PubMed

Neuroscience. 2000;101(3):563-70 PubMed

Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):245-9 PubMed

Free Radic Biol Med. 2004 Dec 15;37(12):1951-62 PubMed

Epilepsia. 2004 Oct;45(10):1202-9 PubMed

J Neurosci. 1996 Feb 15;16(4):1324-36 PubMed

Eur J Neurosci. 2014 Dec;40(12):3711-9 PubMed

Lancet Neurol. 2011 Feb;10(2):173-86 PubMed

Neurobiol Dis. 2014 Apr;64:8-15 PubMed

Mitochondrion. 2012 Jan;12(1):35-40 PubMed

J Neurotrauma. 2010 Jun;27(6):1091-9 PubMed

Neuromuscul Disord. 2005 Apr;15(4):276-86 PubMed

Stroke. 2015 Jun;46(6):1626-32 PubMed

Exp Neurol. 2007 Apr;204(2):597-609 PubMed

Neurobiol Dis. 2012 Mar;45(3):1068-76 PubMed

Sci Rep. 2015 Dec 07;5:17807 PubMed

Neuroscience. 2015 Sep 10;303:160-5 PubMed

J Neurosci. 2012 Aug 15;32(33):11250-8 PubMed

Exp Neurol. 2006 Sep;201(1):105-19 PubMed

Nature. 2006 Oct 19;443(7113):787-95 PubMed

J Biol Chem. 2007 Aug 17;282(33):24146-56 PubMed

Biochim Biophys Acta. 2004 Jul 23;1658(1-2):44-9 PubMed

Neurochem Res. 2008 Dec;33(12):2487-501 PubMed

Neuroscience. 2013 Jan 29;230:39-49 PubMed

Front Cell Neurosci. 2016 May 26;10:136 PubMed

Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9897-902 PubMed

Exp Neurol. 2010 Jul;224(1):325-9 PubMed

Brain Res. 1992 Jun 26;583(1-2):120-6 PubMed

Trends Pharmacol Sci. 1998 Aug;19(8):328-34 PubMed

Eur J Neurosci. 2000 Jul;12(7):2252-64 PubMed

J Neurochem. 2007 Apr;101(1):168-81 PubMed

Nitric Oxide. 2005 Dec;13(4):254-63 PubMed

Neurosci Lett. 2016 Oct 6;632:199-203 PubMed

Biochemistry. 1998 Feb 10;37(6):1613-22 PubMed

Biochem Biophys Res Commun. 2000 Sep 7;275(3):890-4 PubMed

Free Radic Biol Med. 2010 Apr 15;48(8):983-1001 PubMed

Neurochem Int. 2010 Nov;57(6):621-2 PubMed

Free Radic Biol Med. 2013 Sep;62:121-131 PubMed

Epilepsy Research in the Institute of Physiology of the Czech Academy of Sciences in Prague

Protective Effect of Sulforaphane on Oxidative Stress and Mitochondrial Dysfunction Associated with Status Epilepticus in Immature Rats

Sulforaphane Ameliorates Metabolic Changes Associated With Status Epilepticus in Immature Rats

Treatment With Resveratrol Ameliorates Mitochondrial Dysfunction During the Acute Phase of Status Epilepticus in Immature Rats